Frontlight ResearchEarly access
Neuroblastoma trials in Canada
12 of 13 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleSilmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Where
- Montreal, Sherbrooke
- Age
- Up to 30 years
- People
- 104 worldwide
- Run by
- Milton S. Hershey Medical Center
See details and how to joinNCT06541262 - Phase 2/3Taking peopleA Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
- Where
- Toronto
- Age
- 18 months to 18 years
- People
- 144 worldwide
- Run by
- Renaissance Pharma Ltd.
See details and how to joinNCT07549321 · EU 2025-524397-42-00 - Early phase 1Taking peoplePilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
- Where
- Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
- Age
- Up to 6 years
- People
- 15
- Run by
- C17 Council
See details and how to joinNCT06942039 - Phase 3Taking peopleDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Where
- Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, St. John's, Toronto, Vancouver, Winnipeg
- Age
- Up to 30 years
- People
- 478 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06172296 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Calgary, Montreal, Toronto
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 2Taking peoplePediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Where
- Calgary, Montreal, Québec, Sherbrooke
- Age
- Up to 22 years
- People
- 500 worldwide
- Run by
- Giselle Sholler
See details and how to joinNCT02559778 - Phase 3Taking peopleTesting the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Where
- Halifax, Hamilton, Kingston, London, Montreal, Ottawa, Québec, St. John's, Toronto, Vancouver, Winnipeg
- Age
- 365 days to 30 years
- People
- 750 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT03126916 - Phase 2Taking peopleNaxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Where
- Montreal, Québec, Sherbrooke
- Age
- 12 months to 21 years
- People
- 93 worldwide
- Run by
- Giselle Sholler
See details and how to joinNCT05489887 · EU 2025-524140-35-00 - Phase 2Taking people68Ga-DOTATATE Neuroblastoma Imaging Pilot
- Where
- Montreal, Sherbrooke
- Age
- Up to 21 years
- People
- 20
- Run by
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
See details and how to joinNCT04559217 - Phase 1/2Taking peopleStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Where
- Montreal, Toronto, Vancouver
- Age
- 12 months to 30 years
- People
- 90 worldwide
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT04901702 - Phase 1Not yet taking people in CanadaPhase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
- Where
- Montreal, Toronto
- Age
- 2 years to 12 years
- People
- 12
- Run by
- Michel Duval
See details and how to joinNCT07518654 - Phase 3Taking people18F-DOPA II - PET Imaging Optimization
- Where
- Edmonton
- People
- 800
- Run by
- University of Alberta
See details and how to joinNCT04706910